GoAI
Get started
Firefly Neuroscience, Inc. logo

Firefly Neuroscience, Inc.

AIFF

NASDAQTechnologySoftware - Application

Open in GoAI

Previous close

$1.08

$0.00 · 0.00%

Aug 21, 4:00 PM ET

Pre-market

$1.10

+$0.02 · +1.85%

Aug 24, 8:31 AM ET

AIFF company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

64

Undervalued

Momentum

20

Strong Down

Sentiment

48

Mixed

Risk resilience

33

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by mental illnesses and neurological disorders. Its flagship product, Brain Network Analytics, is a sophisticated software platform engineered to aid in the diagnosis and treatment of a diverse range of cognitive and psychiatric conditions. These conditions encompass, but are not limited to, depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. Firefly Neuroscience, Inc. caters to both pharmaceutical companies and medical practitioners.

Industry
Software - Application
Sector
Technology
Headquarters
US
CEO
Greg Lipschitz
Listed since
Nov 28, 2002
Employees
17

Market position

Day range

Current $1.08

52-week range

Current $1.08

Open
$1.09
Previous close
$1.08
Volume
72.22K
0.31× average
Average volume
230.58K
Average daily volume
Market cap
15.98M USD
Beta
0.58
Market reference 1
50-day average
$1.2054
-10.40% below average
200-day average
$1.4324
-24.60% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
8.8M USD
P/E (TTM)
-1.7×
P/B (TTM)
1.52×
P/S (TTM)
8.88×
EV / EBITDA
-0.45×
Earnings yield
-172.20%
Free cash flow yield
-72.08%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
44.58%
Operating margin
-494.16%
Net margin
-506.23%
Return on equity
-260.34%
Return on assets
-189.77%
Return on invested capital
-112.37%

Financial health

Debt / equity
0×
Current ratio
1.43×
Altman Z-score
-6.19
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1564%-4293%-10151%-16008%Gross margin, FY2021: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 37.96%Gross margin, FY2025: 56.48%Operating margin, FY2021: -14543.75%Operating margin, FY2023: -618.07%Operating margin, FY2024: -8500.00%Operating margin, FY2025: -753.50%Net margin, FY2021: -13690.63%Net margin, FY2023: -522.69%Net margin, FY2024: -9685.19%Net margin, FY2025: -1740.98%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 37.96%. Gross margin FY2025 56.48%. Operating margin FY2021 -14543.75%. Operating margin FY2023 -618.07%. Operating margin FY2024 -8500.00%. Operating margin FY2025 -753.50%. Net margin FY2021 -13690.63%. Net margin FY2023 -522.69%. Net margin FY2024 -9685.19%. Net margin FY2025 -1740.98%.

Income trends

Revenue

1.14M USD+957.41%

Operating income

−8.61M USD+6.26%

Net income

−19.88M USD-90.08%
Income trends across reported periods3.24M USD−5.17M USD−13.57M USD−21.98M USDRevenue, FY2021: 32K USDRevenue, FY2023: 498K USDRevenue, FY2024: 108K USDRevenue, FY2025: 1.14M USDOperating income, FY2021: −4.65M USDOperating income, FY2022: −3.33M USDOperating income, FY2023: −3.08M USDOperating income, FY2024: −9.18M USDOperating income, FY2025: −8.61M USDNet income, FY2021: −4.38M USDNet income, FY2022: −3.79M USDNet income, FY2023: −2.6M USDNet income, FY2024: −10.46M USDNet income, FY2025: −19.88M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 32K USD. Revenue FY2023 498K USD. Revenue FY2024 108K USD. Revenue FY2025 1.14M USD. Operating income FY2021 −4.65M USD. Operating income FY2022 −3.33M USD. Operating income FY2023 −3.08M USD. Operating income FY2024 −9.18M USD. Operating income FY2025 −8.61M USD. Net income FY2021 −4.38M USD. Net income FY2022 −3.79M USD. Net income FY2023 −2.6M USD. Net income FY2024 −10.46M USD. Net income FY2025 −19.88M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.14M USD108K USD498K USD—32K USD
Cost of goods sold497K USD67K USD———
Gross profit645K USD41K USD498K USD—32K USD
Research and development1.48M USD1.95M USD741K USD1.27M USD2.93M USD
Selling, general, and administrative7.77M USD7.33M USD2.84M USD1.98M USD1.68M USD
Operating expenses9.25M USD9.22M USD3.58M USD3.33M USD4.69M USD
Interest income89K USD————
Interest expense159K USD69K USD18K USD574K USD135K USD
Depreciation and amortization172K USD67K USD—14K USD429K USD
Operating income−8.61M USD−9.18M USD−3.08M USD−3.33M USD−4.65M USD
Net income−19.88M USD−10.46M USD−2.6M USD−3.79M USD−4.38M USD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.1

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.08-0.52-0.96-1.4Q4 '24Q2 '25Q2 '25Q3 '25Q4 '25Q2 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual -0.61, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 3, 2025: actual -0.45, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual -1.3, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 13, 2025: actual -0.14, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 12, 2025: actual -0.2, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual -0.13, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Jun 30, 2026: actual -0.13, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 10, 2026: actual -0.1, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates552.48K377.67K202.86K28.05KQ4 '24Q2 '25Q2 '25Q3 '25Q4 '25Q2 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual 33K USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 3, 2025: actual 53K USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual 43K USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 13, 2025: actual 299K USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 12, 2025: actual 388K USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual 412K USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Jun 30, 2026: actual 485K USD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 10, 2026: actual 514K USD, estimate —, surprise —, Comparison unavailable.

AIFF news

defenseworld.net

Firefly Neuroscience (NASDAQ:AIFF) vs. Pro Medicus (OTCMKTS:PMCUF) Head-To-Head Analysis

Pro Medicus (OTCMKTS:PMCUF - Get Free Report) and Firefly Neuroscience (NASDAQ: AIFF - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the…

Read source
globenewswire.com

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

KENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced a close…

Read source
globenewswire.com

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee's Recommendation Backs Broader Access to Key Neuroprotective Peptides

– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –

Read source
globenewswire.com

Firefly's AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD

– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”)…

Read source

Corporate actions

Corporate action history

Stock split

Effective Oct 18, 2023

1:10

Stock split

Effective Apr 22, 1997

3:1

Stock split

Effective Jan 31, 1997

3:1

AIFF peers

NVIDIA Corporation logo

NVDA

NVIDIA Corporation

$214.72

-0.98%

Apple Inc. logo

AAPL

Apple Inc.

$309.35

-0.63%

Microsoft Corporation logo

MSFT

Microsoft Corporation

$483.24

+0.43%

Broadcom Inc. logo

AVGO

Broadcom Inc.

$368.45

+1.21%

SK hynix Inc. logo

SKHY

SK hynix Inc.

$163.41

+0.20%

Micron Technology, Inc. logo

MU

Micron Technology, Inc.

$966.78

-0.77%

ETFs holding AIFF

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
119.74K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
52.1K
Weight
0.00%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research AIFF

research.disclaimer